StockData
BioVie Inc. logo

BioVie Inc. (BIVI) stock

BIVINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as BIVIW
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$0.80−0.11 (-12.07%)

Close on Nov 20, 2026Market cap $6.03MP/E –Yield –

BioVie net income

Net income is the profit left for shareholders after every expense, interest and tax.

BioVie's net income for the twelve months ending Jun 30, 2026 was -$22.07M. For fiscal 2026 it was -$22.07M. The highest annual figure on record is -$17.51K in fiscal 2013.

Annual net income

PeriodPeriod endValueChange
FY2026Jun 30, 2026-$22.07M–
FY2025Jun 30, 2025-$17.54M–
FY2024Jun 30, 2024-$32.12M–
FY2023Jun 30, 2023-$50.26M–
FY2022Jun 30, 2022-$26.08M–
FY2021Jun 30, 2021-$130.25M–
FY2020Jun 30, 2020-$16.68M–
FY2018Jun 30, 2018-$2.43M–
FY2017Jun 30, 2017-$1.33M–
FY2016Jun 30, 2016-$431.92K–
FY2015Jun 30, 2015-$233.01K–
FY2014Jun 30, 2014-$321.90K–
FY2013Jun 30, 2013-$17.51K–

Quarterly net income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ2 2026Jun 30, 2026-$5.65M–
Q3 FY2026CQ1 2026Mar 31, 2026-$5.27M–
Q2 FY2026CQ4 2025Dec 31, 2025-$6.07M–
Q1 FY2026CQ3 2025Sep 30, 2025-$5.09M–
Q4 FY2025CQ2 2025Jun 30, 2025-$3.49M–
Q3 FY2025CQ1 2025Mar 31, 2025-$2.79M–
Q2 FY2025CQ4 2024Dec 31, 2024-$7.11M–
Q1 FY2025CQ3 2024Sep 30, 2024-$4.15M–
Q4 FY2024CQ2 2024Jun 30, 2024-$4.94M–
Q3 FY2024CQ1 2024Mar 31, 2024-$8.07M–
Q2 FY2024CQ4 2023Dec 31, 2023-$8.40M–
Q1 FY2024CQ3 2023Sep 30, 2023-$10.71M–
Q4 FY2023CQ2 2023Jun 30, 2023-$9.11M–
Q3 FY2023CQ1 2023Mar 31, 2023-$15.04M–
Q2 FY2023CQ4 2022Dec 31, 2022-$15.69M–
Q1 FY2023CQ3 2022Sep 30, 2022-$10.42M–
Q4 FY2022CQ2 2022Jun 30, 2022-$8.09M–
Q3 FY2022CQ1 2022Mar 31, 2022-$7.04M–
Q2 FY2022CQ4 2021Dec 31, 2021-$5.41M–
Q1 FY2022CQ3 2021Sep 30, 2021-$5.54M-175.5%
Q4 FY2021CQ2 2021Jun 30, 2021-$131.53M–
Q3 FY2021CQ1 2021Mar 31, 2021-$2.99M–
Q2 FY2021CQ4 2020Dec 31, 2020-$3.06M-145.9%
Q1 FY2021CQ3 2020Sep 30, 2020$7.33M–
Q4 FY2020CQ2 2020Jun 30, 2020-$19.15M–
Q3 FY2020CQ1 2020Mar 31, 2020-$366.40K–
Q2 FY2020CQ4 2019Dec 31, 2019$6.67M–
Q1 FY2020CQ3 2019Sep 30, 2019-$3.82M–
Q4 FY2018CQ2 2018Jun 30, 2018-$576.04K–
Q3 FY2018CQ1 2018Mar 31, 2018-$692.56K–
Q2 FY2018CQ4 2017Dec 31, 2017-$502.68K–
Q1 FY2018CQ3 2017Sep 30, 2017-$662.84K–
Q4 FY2017CQ2 2017Jun 30, 2017-$443.04K–
Q3 FY2017CQ1 2017Mar 31, 2017-$178.50K–
Q2 FY2017CQ4 2016Dec 31, 2016-$357.80K–
Q1 FY2017CQ3 2016Sep 30, 2016-$351.34K–
Q4 FY2016CQ2 2016Jun 30, 2016-$269.67K–

More BioVie figures

See a number that looks wrong?